Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This phase II trial studies how well acalabrutinib works in treating patients with mantle cell lymphoma that cannot tolerate ibrutinib. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Epistemonikos ID: 895cc2aad45186571711d7828d6b0b78f547b96e
First added on: May 06, 2024